Pliant Therapeutics Announces Appointment of Gregory P. Cosgrove, M.D., FCCP, as Vice President of Clinical Development, IPF
January 04 2021 - 08:00AM
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage
biopharmaceutical company focused on discovering and developing
novel therapies for the treatment of fibrosis, today announced the
appointment of Gregory P. Cosgrove, M.D., FCCP, as Pliant’s Vice
President of Clinical Development. Dr. Cosgrove brings over 20
years of pulmonary and critical care expertise in academic clinical
research to Pliant and in this role, will lead the strategic
execution of the company’s Idiopathic Pulmonary Fibrosis (IPF)
clinical development program with its lead compound PLN-74809.
PLN-74809 is a dual selective inhibitor of αvβ6/αvβ1, in clinical
development for the treatment of IPF, primary sclerosing
cholangitis (PSC), and COVID-19-associated acute respiratory
distress syndrome (ARDS).
"Greg’s extensive scientific and clinical expertise in the area
of pulmonary fibrosis, as well as his strong relationships within
the research, clinical investigator, and patient communities, will
be instrumental as we further implement the development strategy of
our novel IPF program,” said Bernard Coulie, M.D., Ph.D., President
and Chief Executive Officer of Pliant Therapeutics. “I look forward
to working with Greg and utilizing his broad experiences to enhance
our clinical development efforts and support the progress of
PLN-74809.”
Dr. Cosgrove most recently served as the Chief Medical Officer
of the Pulmonary Fibrosis Foundation, a leading nonprofit
organization dedicated to assisting patients and identifying
effective treatments and a cure for those living with pulmonary
fibrosis. Concurrently, Dr. Cosgrove also held the roles of
Associate Professor within the pulmonology divisions of the
University of Colorado-Denver and National Jewish Health
Departments of Medicine. Dr. Cosgrove has served as principal or
sub investigator in more than 15 clinical trials evaluating IPF
drug candidates, authored or contributed to over 70 publications
and books in pulmonology research, and served as a reviewer for
numerous scientific peer-reviewed journals.
Dr. Cosgrove commented, “As a physician, researcher and
advocate, I believe patients are a cornerstone to changing the
landscape in pulmonary fibrosis. I am excited to join a team that
shares my commitment to the patient and to advancing treatments for
IPF and other fibrotic diseases.”
Dr. Cosgrove received his B.S., magna cum laude, from James
Madison University with highest honors in chemistry and his M.D.
from the Hahnemann University School of Medicine in Philadelphia.
Dr. Cosgrove completed his residency in internal medicine and
post-doctoral fellowships at the University of Colorado Health
Sciences Center Denver and the National Jewish Medical and Research
Center Denver, respectively.
About Pliant Therapeutics, Inc.Pliant
Therapeutics is a clinical stage biopharmaceutical company
focused on discovering and developing novel therapies for the
treatment of fibrosis. Pliant's lead product candidate, PLN-74809,
is an oral small-molecule dual selective inhibitor of avß6 and avß1
integrins that is in development for the treatment of idiopathic
pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or
PSC. PLN-74809 has received Orphan Drug Designation from
the U.S. Food and Drug Administration for both IPF and
PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809
for the treatment of IPF and PSC. Pliant's second product
candidate, PLN-1474, is a small-molecule selective inhibitor of
avß1 for the treatment of liver fibrosis associated with
nonalcoholic steatohepatitis, or NASH, which Pliant has partnered
with Novartis. PLN-1474 is currently undergoing a Phase 1 trial. In
addition to clinical stage programs, Pliant currently has two
preclinical programs targeting oncology and muscular dystrophies.
For additional information about Pliant Therapeutics, visit
www.pliantrx.com and follow us on Twitter, LinkedIn, and
Facebook.
Investor Contact:Christopher KeenanVice
President, Investor Relations and Corporate CommunicationsPliant
Therapeutics, Inc.ir@pliantrx.com
Media Contact:Cambria FuquaCanale
Communicationscambria.fuqua@canalecomm.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/d92466b0-df39-4775-b95e-17fc5f8190ad.
Pliant Therapeutics (NASDAQ:PLRX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Pliant Therapeutics (NASDAQ:PLRX)
Historical Stock Chart
From Mar 2023 to Mar 2024